02474nas a2200301 4500008004100000245015800041210006900199260001800268300001000286490000700296520159200303100001601895700001701911700001801928700001301946700001801959700001501977700001801992700001402010700001602024700001602040700001602056700001702072700001702089700001602106700001402122856003602136 2022 eng d00aBioactive Compounds from Mangosteen (Garcinia mangostana L.) as an Antiviral Agent via Dual Inhibitor Mechanism against SARSCoV- 2: An In Silico Approach0 aBioactive Compounds from Mangosteen Garcinia mangostana L as an  cFebruary 2022 a85-900 v143 a

Severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) is the virus that causes COVID-19 which is responsible for respiratory illness infection in humans. The virus was first identified in China in 2019 and later spread to other countries worldwide. This study aims to identify the bioactive compounds from mangosteen (Garcinia mangostana L.) as an antiviral agent via dual inhibitor mechanisms against two SARS-CoV-2 proteases through the in silico approach. The three-dimensional structure of various bioactive compounds of mangosteen from the database was examined. Furthermore, all the target compounds were analyzed for drug, antiviral activity prediction, virtual screening, molecular interactions, and threedimensional structure visualization. It aimed to determine the potential of the bioactive compounds from mangosteen that can serve as antiviral agents to fight SARS-CoV-2. Results showed that the bioactive compounds from mangosteen have the prospective to provide antiviral agents that contradict the virus via dual inhibitory mechanisms. In summary, the binding of the various bioactive compounds from mangosteen results in low binding energy and is expected to have the ability to induce any activity of the target protein binding reaction. Therefore, it allows various bioactive compounds from mangosteen to act as dual inhibitory mechanisms for COVID-19 infection.

Key words: Antiviral agent, COVID-19, Garcinia mangostana L., In silico approach, SARS-CoV-2.

1 aAnsori, ANM1 aKharisma, VD1 aParikesit, AA1 aDian, FA1 aProbojati, RT1 aRebezov, M1 aScherbakov, P1 aBurkov, P1 aZhdanova, G1 aMikhalev, A1 aAntonius, Y1 aPratama, MRF1 aSumantri, NI1 aSucipto, TH1 aZainul, R uhttps://phcogj.com/article/1740